Press "Enter" to skip to content

Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer – Yahoo Finance

admin 0

Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer  Yahoo Finance

Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the …

“lymphoma cancer” – Google News

(Visited 3 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *